[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"petct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:petct":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,48,74,98,120,144,167,188,207,229,252,272,297,321,346,368,386,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645163","dll3-targeted-petct-in-small-cell-lung-cancer-100645163",false,"NCT07677787","DLL3-Targeted PET\u002FCT in Small Cell Lung Cancer","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.",[27,28,29,30],"PET\u002FCT","Small Cell Lung Cancer ( SCLC )","DLL3-targeted PET\u002FCT","Delta-like Protein 3",[29,27,32,33,34],"Small Cell Lung Cancer","SCLC","Delta-like protein 3","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2026-05-09",{"date":43,"type":21},"2028-05-31",{"name":45,"class":46},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100630454","cadherin-3cdh3-targeted-pet-in-lung-malignant-tumors-100630454","NCT07487883","Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to Evaluate CDH3-targeted Positron Emission Tomography (PET) for Lung Malignant Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;\n2. Availability of complete clinical and imaging data;\n3. Life expectancy ≥ 12 weeks;\n4. Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹\u002FL or neutrophils ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, Hb ≥ 90 g\u002FL; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT\u002FAST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;\n5. Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria;\n6. Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks;\n7. Ability to provide adequate tumor tissue for testing and research.\n\nExclusion Criteria:\n\n1. Women who are planning pregnancy, pregnant, or breastfeeding;\n2. History of other malignant tumors or prior receipt of other anti-tumor therapies;\n3. Poor or missing PET scan image quality of the probe that fails to meet analysis standards;\n4. Presence of claustrophobia or other mental illnesses;\n5. Any other conditions deemed by the investigators as inappropriate for participation in this study.",{"count":56,"type":21},80,"OBSERVATIONAL","Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.",[60,61,62,27],"Non-Small Cell Lung Cancer","Malignant Neoplasm","Pulmonary Nodules",[61,27,60,64],"Pulmonary nodules","2026-03-27",{"date":67,"type":39},"2026-04-02",{"date":69,"type":39},"2026-03-18",{"date":71,"type":21},"2027-07-30",{"name":73,"class":46},"Peking University People's Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100631304","fap-targeted-petnir-in-lung-malignant-tumors-100631304","NCT07498933","FAP-targeted PET\u002FNIR in Lung Malignant Tumors","Visualization Study on Tumor Progression Mechanisms and Key Molecular Functions in Neoadjuvant Immunotherapy for Lung Cancer: Preoperative Efficacy Prediction and Intraoperative Fluorescence Navigation","Inclusion Criteria:\n\n* Age between 18 and 70 years old;\n* Have complete clinical and imaging data;\n* Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;\n* Able to retain sufficient tumor tissue for testing and research;\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Previously combined with other malignant tumors or received other anti-tumor treatments;\n* Failure to collect sufficient tumor tissue for testing and research;\n* The duration of neoadjuvant therapy is less than 3 cycles;\n* The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;\n* Lack of clinical and imaging data;\n* There are situations where other researchers consider it inappropriate to participate in this study","70 Years",{"count":83,"type":21},200,"Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy\u002Fimmunotherapy\u002Fcombination therapy), FAPI-PET\u002FCT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET\u002Ffluorescence were compared and analyzed.",[60,27,86],"Neoadjuvant Therapy",[88,89,86,60],"PET Imaging","NIR Imaging","2026-03-26",{"date":92,"type":39},"2026-04-01",{"date":94,"type":39},"2025-06-03",{"date":96,"type":21},"2027-12-31",{"name":73,"class":46},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":104,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":47},"100559072","68ga-fapi-petct-evaluation-of-axillary-lymph-node-status-after-neoadjuvant-therapy-in-patients-with-clinical-axillary-lymph-node-positive-breast-cancer-100559072","NCT06559371","68Ga FAPI PET\u002FCT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer","Inclusion Criteria:\n\n* Female patients aged 18 and above\n* ECOG score 0-2 points\n* Pathological confirmation of malignant breast tumor\n* Clinical axillary lymph node positivity (cN+)\n* Completed at least 3 courses of neoadjuvant therapy and subjected to undergo surgical treatment\n* Informed consent form signed\n\nExclusion Criteria:\n\n* Distant metastasis\n* Unable to complete the proposed neoadjuvant therapy plan\n* Pregnancy","FEMALE",{"count":106,"type":21},150,"The goal of this observational study is to learn whether 68Ga-FAPI PET\u002FCT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer. The main question it aims to answer is:\n\nCould 68Ga-FAPI PET\u002FCT effectively evaluate axillary lymph node after neoadjuvant treatment for breast cancer? Participants will have a 68Ga-FAPI PET\u002FCT test between last neoadjuvant therapy and surgery.",[109,27],"BREAST CANCER",[109,27],"2025-12-21",{"date":113,"type":39},"2025-12-29",{"date":115,"type":39},"2024-08-30",{"date":117,"type":21},"2026-06-30",{"name":119,"class":46},"Kunwei Shen",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":18,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":47},"100611548","68ga-xacp3-petct-in-prostate-cancer-100611548","NCT07242014","68Ga-XACP3 PET\u002FCT in Prostate Cancer","PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET\u002FCT) and 68Ga-XACP3 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","MALE",{"count":129,"type":21},60,[24],"The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET\u002FCT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET\u002FCT.",[133,27,134],"Prostate Cancer","ACP3",[133,27,134],"2025-11-17",{"date":138,"type":39},"2025-11-21",{"date":140,"type":39},"2025-09-01",{"date":142,"type":21},"2027-10-01",{"name":45,"class":46},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":47},"100604621","petct-for-trop2-adc-response-evaluation-nsclc-100604621","NCT07151898","PET\u002FCT for Trop2 ADC Response Evaluation NSCLC","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in NSCLC","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months",{"count":152,"type":21},50,"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.",[155,156,27],"NSCLC","Trop2",[155,156,27,158],"Trop2-ADC","2025-08-26",{"date":161,"type":39},"2025-09-03",{"date":163,"type":39},"2025-05-01",{"date":165,"type":21},"2027-05-01",{"name":45,"class":46},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":104,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100596532","petct-for-trop2-adc-response-evaluation-cancers-100596532","NCT07046689","PET\u002FCT for Trop2 ADC Response Evaluation Cancers","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in Advanced Breast Cancer","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months",{"count":152,"type":21},"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.",[177,156,27],"Breast Cancer",[179,156,27,158],"Breast cancer","2025-07-14",{"date":182,"type":39},"2025-07-15",{"date":184,"type":39},"2024-11-01",{"date":186,"type":21},"2026-12-31",{"name":45,"class":46},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":47},"100596533","68ga-my6349-petct-in-solid-tumors-100596533","NCT07046702","68Ga-MY6349 PET\u002FCT in Solid Tumors","68Ga-MY6349 PET\u002FCT in Solid Tumors and Compared With 18F-FDG PET\u002FCT","Inclusion Criteria:\n\n* adult patients (aged 18 years or older)\n* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)\n* patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET\u002FCT scans\n* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* patients with pregnancy\n* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent",{"count":196,"type":21},300,"The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET\u002FCT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET\u002FCT.",[199,156,27],"Solid Tumor",[201,156,27],"Solid tumor",{"date":182,"type":39},{"date":204,"type":39},"2024-12-10",{"date":186,"type":21},{"name":45,"class":46},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":47},"100458923","cxcr4-targeted-petct-imaging-in-hematological-malignancies-100458923","NCT05255926","CXCR4-targeted PET\u002FCT Imaging in Hematological Malignancies","An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET\u002FCT Imaging for Evaluation of Hematological Malignancies","Inclusion Criteria:\n\n1. Volunteer to participate and sign an informed consent form;\n2. 18 ≤ Age ≤ 90 years;\n3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;\n4. Willing and able to follow schedule visits, treatment plans and laboratory tests.\n\nExclusion Criteria:\n\n1. pregnancy or breastfeeding;\n2. Allergic to CXCR4-targeted tracers or excipients;\n3. Fasting blood glucose level exceeded 11.0 mmol\u002FL prior to injection of 18F-FDG;\n4. Those who cannot complete PET\u002FCT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;\n5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.","90 Years",{"count":196,"type":21},[24],"Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality. Although 18F-FDG PET\u002FCT remains the most commonly used molecular imaging modality, its limited specificity can result in false-positive or false-negative findings, especially in indolent or low-metabolism subtypes, thereby hampering accurate diagnosis, staging, and therapeutic evaluation. C-X-C chemokine receptor type 4 (CXCR4) is frequently overexpressed in a broad spectrum of hematologic malignancies and correlates with aggressive disease and unfavorable outcomes. CXCR4-targeted molecular imaging using \\^68Ga-pentixafor PET\u002FCT has shown promise for improved disease characterization. This prospective study aims to systematically compare 68Ga-pentixafor PET\u002FCT with 18F-FDG PET\u002FCT in terms of diagnostic performance, staging accuracy, risk stratification, and prognostic relevance in patients with hematological malignancies. Furthermore, the study will incorporate artificial intelligence-based image analysis to enhance lesion detection, automate quantitative assessments, and support personalized clinical decision-making.",[219,27,220],"CXCR4","Hematological Malignancy","2025-06-22",{"date":223,"type":39},"2025-06-26",{"date":225,"type":39},"2022-03-01",{"date":186,"type":21},{"name":228,"class":46},"Zhongnan Hospital",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":236,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":47},"100441881","68ga-fapi-petct-in-malignant-tumors-100441881","NCT05034146","68Ga-FAPI PET\u002FCT in Malignant Tumors","The Diagnostic Efficiency of 68Ga-FAPI PET\u002FCT in Malignant Tumors","Inclusion Criteria:\n\nVolunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor\n\nExclusion Criteria:\n\nFemale patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month",true,"88 Years",{"count":239,"type":21},500,[24],"Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.",[243,27,61],"Fibroblast Activation Protein Inhibitor","2025-05-31",{"date":246,"type":39},"2025-06-05",{"date":248,"type":39},"2021-02-23",{"date":250,"type":21},"2025-12-31",{"name":228,"class":46},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":259,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":47},"100441609","exploring-the-application-value-of-pet-molecular-imaging-targeting-fap-in-oral-squamous-cell-carcinoma-100441609","NCT05030597","Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma","FAPI-OSCC","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent;\n2. Aged 18\\~70 years;\n3. Clinically highly suspected oral cancer and recurrence after treatment (Newly diagnosed patients: Scheduled for surgery or neoadjuvant therapy followed by surgery);\n4. Ability to complete baseline and follow-up PET\u002FCT (Follow-up FAPI PET\u002FCT applies only to locally advanced patients undergoing neoadjuvant therapy.).\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, or women planning pregnancy during the trial period;\n2. Known hypersensitivity to FAPI, FDG, or their components, or history of severe allergic reactions;\n3. People with poor general condition, their heart, lung, liver, kidney and other important organ functions cannot tolerate surgery;\n4. Before the injection of 18F-FDG, the fasting blood glucose level exceeded 11.0 mmol\u002FL;\n5. Claustrophobia or inability to tolerate PET\u002FCT imaging (Those who cannot tolerate lying supine for 15\\~30 minutes.);\n6. Participation in another interventional clinical trial within 30 days prior to enrollment, or planned participation during this study.",{"count":260,"type":21},100,"In this prospective study, the investigators will use integrated PET\u002FCT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore the application value of FAP-targeted molecular imaging in the diagnosis and staging for oral cancer. This study also aims to explore the application value of FAPI imaging in evaluating treatment response for oral cancer.",[27,263,264],"FAPI","Oral Cancer","2025-05-21",{"date":267,"type":39},"2025-05-28",{"date":269,"type":39},"2021-09-15",{"date":250,"type":21},{"name":228,"class":46},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":47},"100503462","integrin-v6-targeted-pet-in-malignant-tumors-100503462","NCT05835570","Integrin αvβ6-targeted PET in Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography (PET) for Malignant Tumors","Inclusion Criteria:\n\n* Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;\n* Age ≥18 years, regardless of gender;\n* No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET\u002FCT;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n* Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;\n* Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.\n\nExclusion Criteria:\n\n* Known allergy to injection or its excipients;\n* Severe liver or renal dysfunction;\n* Claustrophobia or other psychiatric disorders;\n* History of other malignant tumors;\n* Participation in another clinical trial within 30 days prior to PET\u002FCT scan;\n* Pregnant or breastfeeding women;\n* Refusal to participate or request for withdrawing from the clinical study;\n* Other conditions deemed unsuitable for inclusion by investigator.","85 Years",{"count":83,"type":21},"Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.",[61,27,60,283],"Breast Cancer, Metastatic",[285,179,286,287,288],"Non-small cell lung cancer","Integrin-αvβ6","[68Ga]Ga-Trivehexin","Malignant tumors","2025-04-27",{"date":291,"type":39},"2025-04-30",{"date":293,"type":39},"2023-01-01",{"date":295,"type":21},"2025-12-30",{"name":228,"class":46},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":47},"100493586","petct-follow-up-for-head-and-neck-squamous-cell-carcinoma-100493586","NCT05707078","PET\u002FCT Follow up for Head and Neck Squamous Cell Carcinoma","PET Follow","Inclusion Criteria:\n\n* Informed consent\n* Age above 18\n* Completed curative treatment for HNSCC of the oral cavity, nasopharynx, oropharynx, hypopharynx or larynx\n\nExclusion Criteria:\n\n* Patient refusal\n* Patients with clinical N0 neck\n* Patients who had neck dissections prior to radiotherapy\n* Patients who are clinical inoperable for any reason",{"count":305,"type":21},600,[24],"PET\u002FCT follow up for Head and Neck Squamous Cell Carcinoma The following is a presentation of a prospective protocol, named PET\u002FCT follow up for Head and Neck Squamous Cell Carcinoma (PET Follow), including patients who have completed radiotherapy treatment for squamous cell carcinoma of the head and neck (HNSCC).\n\nThe purpose of this study is to investigate the diagnostic performance of 18F-fluorodeoxy-D-glucose (FDG) Positron Emission Tomography\u002F Computed Tomography (PET\u002FCT) in patients with HNSCC after curative intended treatment.",[309,27],"Head and Neck Squamous Cell Carcinoma",[27,311],"HNSCC","2025-04-02",{"date":314,"type":39},"2025-04-06",{"date":316,"type":39},"2023-03-07",{"date":318,"type":21},"2030-12-30",{"name":320,"class":46},"Rigshospitalet, Denmark",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":329,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":338,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":47},"100586520","granzyme-b-targeted-pet-imaging-monitoring-tumor-responses-to-immunotherapy-100586520","NCT06916442","Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy","A Single-Arm, Open-Label, Exploratory Study of Granzyme B-Targeted PET Imaging for Evaluating Tumor Response to Immunotherapy in Solid Tumors","GZMB_PET","Inclusion Criteria\n\n1. Voluntarily participate and sign the written informed consent form.\n2. Aged 18 to 90 years (inclusive), regardless of gender.\n3. Treatment-naïve patients with pathologically confirmed malignant solid tumors scheduled to receive immunotherapy.\n4. Willing and able to adhere to scheduled visits, treatment plans, and laboratory tests.\n\nExclusion Criteria\n\n1. Pregnant or lactating patients.\n2. Patients with a known allergy to GZMB-targeted imaging agents or synthetic excipients.\n3. Fasting blood glucose level exceeding 11.0 mmol\u002FL prior to 18F-FDG administration.\n4. Patients unable to undergo PET\u002FCT imaging (e.g., inability to lie supine, claustrophobia, severe anxiety related to radiation exposure).\n5. Patients with poor compliance or other factors deemed by the investigator to preclude participation in the study.",{"count":83,"type":21},"Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden. Molecular imaging enables the non-invasive, in vivo visualization of tumorigenesis and progression at the molecular level. Compared to traditional morphology-based imaging techniques, molecular imaging provides more precise information for early tumor diagnosis, treatment efficacy assessment, and clinical disease management. 18F-FDG PET\u002FCT imaging is currently the most widely used molecular imaging modality. However, under immunotherapy, FDG accumulates extensively in activated T cells, leading to increased false-positive evaluations. It fails to effectively distinguish metabolic hyperactivity between proliferative tumor cells (indicative of true progressive disease) and infiltrating immune cells (associated with pseudoprogression), thereby complicating the assessment of immunotherapy efficacy. Therefore, exploring novel molecular imaging probes with high specificity is of critical importance for patients undergoing tumor immunotherapy, as it can lead to more accurate evaluation of treatment efficacy. Granzyme B (GZMB), a serine protease released from cytoplasmic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, induces apoptosis in target cells, particularly tumor cells-a central mechanism of tumor immunotherapy. This makes GZMB a promising molecular target for evaluating immunotherapy efficacy. This study aims to assess tumor immunotherapy outcomes using GZMB-targeted PET imaging and compare its performance with 18F-FDG PET\u002FCT. The goal is to achieve timely and accurate efficacy evaluation and longitudinal monitoring, identify potential beneficiaries, optimize clinical decision-making, and ultimately deliver personalized precision treatment to improve overall treatment outcomes.",[27,332,333],"Solid Tumors, Adult","Solid Tumors, Advanced Solid Tumors",[335,88,336,337],"Granzyme B","Immunotherapy Response","Diagnostic Efficacy","NOT_YET_RECRUITING","2025-03-31",{"date":341,"type":39},"2025-04-08",{"date":343,"type":21},"2025-04-01",{"date":96,"type":21},{"name":228,"class":46},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":236,"sex":127,"minAge":17,"maxAge":214,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":365,"locationsCount":47},"100574211","early-phase-1-head-to-head-comparison-of-18falf-psma-n5-with-18ff-dcfpyl-petct-in-pca-diagnosis-recurrence-and-metastasis-100574211","NCT06756334","Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET\u002FCT in PCa Diagnosis, Recurrence, and Metastasis","Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET\u002FCT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study","Inclusion Criteria:\n\n* Aged from 18 to 90 years old;\n* Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);\n* Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;\n* simultaneous \\[18F\\]AlF-PSMA-N5 and \\[18F\\]F-DCFPyL examinations within two weeks;\n* Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate with the examination;\n* Concurrent malignant tumors;\n* Previous alcohol allergy;\n* Patients with liver and kidney dysfunction;\n* Other circumstances deemed by the investigator to be inappropriate for trial participation.",{"count":354,"type":21},30,[356],"EARLY_PHASE1","To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \\[18F\\]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \\[18F\\]F-DCFPyL.",[133,27],"2024-12-25",{"date":361,"type":39},"2025-01-03",{"date":363,"type":39},"2024-12-19",{"date":250,"type":21},{"name":366,"class":367},"Anhui Provincial Hospital","OTHER_GOV",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":236,"sex":127,"minAge":17,"maxAge":214,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":47},"100551624","early-phase-1-head-to-head-comparison-of-18ff-psma-n5-with-68gaga-psma-11-petct-in-pca-diagnosis-recurrence-and-metastasis-100551624","NCT06462508","Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET\u002FCT in PCa Diagnosis, Recurrence, and Metastasis","Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET\u002FCT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study","Inclusion Criteria:\n\n* Aged from 18 to 90 years old;\n* Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);\n* Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;\n* simultaneous \\[18F\\]F-PSMA-N5 and \\[68Ga\\]Ga-PSMA-11 examinations within two weeks;\n* Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate with the examination;\n* Concurrent malignant tumors;\n* Previous alcohol allergy;\n* Patients with liver and kidney dysfunction;\n* Other circumstances deemed by the investigator to be inappropriate for trial participation.",{"count":354,"type":21},[356],"To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \\[18F\\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \\[68Ga\\]Ga-PSMA-11.",[133,27],"2024-06-12",{"date":381,"type":39},"2024-06-17",{"date":383,"type":39},"2024-04-20",{"date":250,"type":21},{"name":366,"class":367},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":236,"sex":127,"minAge":17,"maxAge":214,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":401,"locationsCount":47},"100551623","early-phase-1-head-to-head-comparison-of-18ff-psma-n5-with-18ff-psma-1007-petct-in-pca-diagnosis-recurrence-and-metastasis-100551623","NCT06462495","Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET\u002FCT in PCa Diagnosis, Recurrence, and Metastasis","Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET\u002FCT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study","Inclusion Criteria:\n\n* Aged from 18 to 90 years old;\n* Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);\n* Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;\n* simultaneous \\[18F\\]F-PSMA-N5 and \\[18F\\]F-PSMA-1007 examinations within two weeks;\n* Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate with the examination;\n* Concurrent malignant tumors;\n* Previous alcohol allergy;\n* Patients with liver and kidney dysfunction;\n* Other circumstances deemed by the investigator to be inappropriate for trial participation.",{"count":354,"type":21},[356],"To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \\[18F\\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \\[18F\\]F-PSMA-1007.",[133,27],{"date":381,"type":39},{"date":399,"type":39},"2024-04-10",{"date":250,"type":21},{"name":366,"class":367},{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":410,"targetDuration":412,"studyType":57,"phases":4,"briefSummary":413,"conditions":414,"keywords":417,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":47},"100540698","promise-pet-registry-on-psma-pet-and-outcome-in-prostate-cancer-100540698","NCT06320223","PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer","PROMISE-PET","Inclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer.",{"count":411,"type":21},10000,"10 Years","Background:\n\nPROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.\n\nNeed:\n\nImproved prognostication across various stages of prostate cancer is needed for management guidance and study design.\n\nAim:\n\n1. To assess the prognostic value of PSMA PET\n2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages\n\nInclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer",[133,27,415,416],"Survivorship","PSMA",[133,27,415,416,418,419,420,421],"Nuclear Medicine","Imaging","Oncology","Urology","2024-03-15",{"date":424,"type":39},"2024-03-20",{"date":426,"type":39},"2024-03-05",{"date":428,"type":21},"2035-03-05",{"name":430,"class":46},"University Hospital, Essen"]